Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 23:14:1112917.
doi: 10.3389/fphar.2023.1112917. eCollection 2023.

Self-reactive IgE and anti-IgE therapy in autoimmune diseases

Anna Olewicz-Gawlik  1   2 , Arleta Kowala-Piaskowska  2
Affiliations
Review

Self-reactive IgE and anti-IgE therapy in autoimmune diseases

Anna Olewicz-Gawlik et al. Front Pharmacol. .

Abstract

Growing evidence indicates the pathogenic role of autoreactive IgE in autoimmune diseases. Incidence of autoimmune and allergic diseases in the industrialized countries is consistently icreasing, thus leading to concerted efforts to comprehend the regulation of IgE-mediated mechanisms. The first reports of a presence of IgE autoantibodies in patients with autoimmune diseases have been published a long time ago, and it is now recognized that self-reactive IgE can mediate inflammatory response in bullous pemhigoid, systemic lupus erythematosus, chronic urticaria, and atopic dermatitis. The advances in understanding the pathomechanisms of these disorders brought to a successful use of anti-IgE strategies in their management. The present review discusses the current state of knowledge on the IgE-mediated autoimmunity and anti-IgE treatment, and pave the way for further exploration of the subject.

Keywords: Immunoglobulin E; anti-IgE; autoimmune disease; autoimmunity; omalizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

References

    1. Acharya M., Borland G., Edkins A. L., Maclellan L. M., Matheson J., Ozanne B. W., et al. (2010). CD23/FcεRII: Molecular multi-tasking. Clin. Exp. Immunol. 162 (1), 12–23. 10.1111/j.1365-2249.2010.04210.x - DOI - PMC - PubMed
    1. Akbaş P. E., Kocatürk E., Tüzün B., Köklü N., Yazıcı A. C., Topal İ. (2017). Omalizumab for the treatment of hyperimmunoglobulin E syndrome: A 12-year-old case. Dermatol Sin. 35 (1), 48–49. 10.1016/j.dsi.2016.07.002 - DOI
    1. Akdis C. A. (2021). Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat. Rev. Immunol. 21 (11), 739–751. 10.1038/s41577-021-00538-7 - DOI - PubMed
    1. Alonso-Bello C. D., Jiménez-Martínez M. D. C., Vargas-Camaño M. E., Hierro-Orozco S., Ynga-Durand M. A., Berrón-Ruiz L., et al. (2019). Partial and transient clinical response to omalizumab in IL-21-induced low STAT3-phosphorylation on hyper-IgE syndrome. Case Rep. Immunol. 2019, 6357256. 10.1155/2019/6357256 - DOI - PMC - PubMed
    1. Altrichter S., Frischbutter S., Fok J. S., Kolkhir P., Jiao Q., Skov P. S., et al. (2020). The role of eosinophils in chronic spontaneous urticaria. J. Allergy Clin. Immunol. 145 (6), 1510–1516. 10.1016/j.jaci.2020.03.005 - DOI - PubMed

LinkOut - more resources